欢迎您注册蒲公英
您需要 登录 才可以下载或查看，没有帐号？立即注册
x
本帖最后由 小刚刚 于 2017-3-22 16:03 编辑
HITGEN AND MSDENTER ResearchCollaboration Chengdu, China，22nd March,2017, HitGen Ltd announced that the company has enteredinto a collaboration with MSD, known as Merck in the United States and Canada,to discover novelchemical leads for multiple therapeutic targets of interest to MSD. According to this agreement, HitGen will deploy its core technology platform, basedon DNA-encoded library design, synthesis and screening.. The novel leads identifiedwill be licensed exclusively to MSD. Under the terms of the agreement, HitGen will receive an upfrontpayment and be eligible for milestone payments from MSD.
“We are very pleased to establish thiscollaboration with MSD, one of the leadingpharmaceutical companies in the world. Through thiscollaboration, we will work closely with MSDscientists to discover novel lead compounds aimed at bringing new medicines toaddress unmet medical needs,” said Dr. Jin Li, Chairman of theBoard and Chief Executive Officer of HitGen.
“Agreements like this that facilitate theapplication of potentially enabling new platform technologies are a key elementof our collaboration strategy,” said Dr. Richard Tillyer, senior vicepresident, MSD Global Chemistry. “We look forward to working with scientists atHitGen to apply this platform towards the discovery of novel therapeuticcandidates.”
ENDS About HitGen Ltd HitGenis an innovation driven life science company with headquarters and main research facilities based inChengdu, China and with laboratory in Houston,Texas， USA. HitGenhas established a unique platform for drug discovery research. Our DNA encoded chemical libraries (DELs) contain more than 10 billion novel, diverse,drug-like compounds. Thesecompounds are members of DELssynthesised frommany hundreds of distinct chemical scaffolds, designed with tractable chemistryand proven results for finding drug leads against targets from known and novelprotein classes. HitGen is working with multiple pharmaceutical,biotech companies and research institutes to discover and develop noveltherapeutics of the future. Forfurther information, please contact Dr.Jin Li, Chairman & CEO， HitGen Ltd. Tel: +86 28 85197385 Dr.Barry Morgan, Chief Scientific Officer，HitGenLtd. Tel: +1 5088409646 | 
|手机版|蒲公英|ouryao|蒲公英
( 京ICP备14042168号-1 ) 增值电信业务经营许可证编号：京B2-20243455 互联网药品信息服务资格证书编号：(京)-非经营性-2024-0033
发表于 2017-3-22 16:00:03
置顶卡
变色卡
